The NHS will not offer a drug that gives patients with advanced breast cancer a last hope because it is too expensive.
Women with HER2-positive breast cancer, which has spread to other parts of their body and has not responded to initial treatment, can see their lives extended by around six months by Kadcyla.
However, the National Institute for Health and Care Excellence (Nice) has ruled that at around £90,000 per patient, the drug is too expensive to recommend for widespread use in the health service.
The NHS financial watchdog criticised Roche, who manufactures the drug, for not discounting the treatment further.
Roche said that is had offered to cut the price of the drug and will be appealing Nice's decision.
More top news
Sir Philip Green said he is "sad and sorry for all the BHS people caught up in this horrid story".
This evening it'll become largely dry across the UK as the showers in the west gradually die down.
In the run-up to the Rio Olympics, ITV News has spoken to four Team GB athletes who are aiming for gold. Today we speak to Laura Trott.